NASDAQ:ALRN - Aileron Therapeutics Stock Price, Forecast & News

Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN."

Aileron Therapeutics Inc (NASDAQ:ALRN) issued its quarterly earnings results on Thursday, November, 7th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.23) by $0.05. View Aileron Therapeutics' Earnings History.

Aileron Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, April 3rd 2020. View Earnings Estimates for Aileron Therapeutics.

3 analysts have issued 1-year price objectives for Aileron Therapeutics' stock. Their forecasts range from $5.00 to $6.00. On average, they expect Aileron Therapeutics' stock price to reach $5.50 in the next year. This suggests a possible upside of 666.6% from the stock's current price. View Analyst Price Targets for Aileron Therapeutics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aileron Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aileron Therapeutics.

Media coverage about ALRN stock has been trending very negative on Monday, according to InfoTrie Sentiment. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aileron Therapeutics earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Aileron Therapeutics.

Aileron Therapeutics saw a drop in short interest during the month of January. As of January 31st, there was short interest totalling 330,800 shares, a drop of 36.7% from the January 15th total of 522,600 shares. Based on an average daily trading volume, of 357,500 shares, the short-interest ratio is presently 0.9 days. Approximately 2.0% of the company's shares are sold short. View Aileron Therapeutics' Current Options Chain.

Some companies that are related to Aileron Therapeutics include Elite Pharmaceuticals (ELTP), Stealth BioTherapeutics (MITO), Onconova Therapeutics (ONTX), Eyenovia (EYEN), Trevena (TRVN), Chembio Diagnostics (CEMI), Cumberland Pharmaceuticals (CPIX), Entasis Therapeutics (ETTX), Catabasis Pharmaceuticals (CATB), CTI BioPharma (CTIC), DiaMedica Therapeutics (DMAC), Aridis Pharmaceuticals (ARDS), Soligenix (SNGX), ASLAN PHARMACEU/ADR (ASLN) and Q BioMed (QBIO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aileron Therapeutics investors own include Portola Pharmaceuticals (PTLA), Agile Therapeutics (AGRX), Lexicon Pharmaceuticals (LXRX), Nabriva Therapeutics (NBRV), Aduro BioTech (ADRO), Iovance Biotherapeutics (IOVA), Senseonics (SENS), Abeona Therapeutics (ABEO), Amarin (AMRN) and Corbus Pharmaceuticals (CRBP).

(ALRN) raised $61 million in an initial public offering (IPO) on Thursday, June 29th 2017. The company issued 3,800,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Aileron Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (1.77%), Blair William & Co. IL (1.25%), Banco Bilbao Vizcaya Argentaria S.A. (0.36%), Geode Capital Management LLC (0.33%) and Game Plan Financial Advisors LLC (0.18%). Company insiders that own Aileron Therapeutics stock include Apple Tree Partners Ii Lp, Bioventures Ltd Novartis, Donald Dougherty, Jeffrey Allen Bailey, John P Phd Longenecker, Kathryn Gregory, Manuel Aivado, Rickenbach Josef H Von and Vojo Vukovic. View Institutional Ownership Trends for Aileron Therapeutics.

ALRN stock was purchased by a variety of institutional investors in the last quarter, including Blair William & Co. IL, Renaissance Technologies LLC, Banco Bilbao Vizcaya Argentaria S.A., Game Plan Financial Advisors LLC and Geode Capital Management LLC. Company insiders that have bought Aileron Therapeutics stock in the last two years include Donald Dougherty, Jeffrey Allen Bailey, John P Phd Longenecker, Kathryn Gregory, Manuel Aivado, Rickenbach Josef H Von and Vojo Vukovic. View Insider Buying and Selling for Aileron Therapeutics.

Shares of ALRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ALRN stock can currently be purchased for approximately $0.72.

Aileron Therapeutics has a market capitalization of $19.95 million. The company earns $-31,550,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis. Aileron Therapeutics employs 23 workers across the globe.View Additional Information About Aileron Therapeutics.

The official website for Aileron Therapeutics is http://www.aileronrx.com/.

Aileron Therapeutics' mailing address is 490 Arsenal Way, Watertown MA, 02472. The company can be reached via phone at 617-995-0900 or via email at [email protected]